3 stocks crushed by the market this week   07-03-14
Upcoming SlideShare
Loading in...5
×

Like this? Share it with your network

Share
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Be the first to comment
    Be the first to like this
No Downloads

Views

Total Views
5,557
On Slideshare
930
From Embeds
4,627
Number of Embeds
12

Actions

Shares
Downloads
0
Comments
0
Likes
0

Embeds 4,627

http://www.fool.com 4,475
http://m.fool.com 127
http://www.barchart.com 9
http://barchartjson.websol.barchart.com 5
https://cms.fool.com 2
http://translate.googleusercontent.com 2
http://cwisecarver.www.fool.com 2
http://www.google.com 1
http://www.seattlepi.com 1
http://www.greenwichtime.com 1
http://131.253.14.125 1
http://www.mysanantonio.com 1

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
    No notes for slide
  • http://www.fool.com/investing/general/2014/02/06/why-medidata-solutions-inc-shares-dipped.aspx
  • http://www.fool.com/investing/general/2014/02/06/why-medidata-solutions-inc-shares-dipped.aspx
  • http://www.fool.com/investing/general/2014/02/06/why-affymetrix-inc-shares-dropped.aspx <br />
  • http://www.fool.com/investing/general/2014/02/06/why-medidata-solutions-inc-shares-dipped.aspx

Transcript

  • 1. 3 Stocks Crushed by the Market This Week
  • 2. Some fireworks soared into the sky this 4th of July. But some turned out to be duds. It works that way in the stock market as well. Here are three health-care stocks that had more fizzle than sizzle this week.
  • 3. Shares of the diagnostic instrumentation developer dropped 12% for the week. Accelerate Diagnostics (NASDAQ:AXDX) Source: Yahoo! Finance
  • 4. • Accelerate Diagnostics was dropped from the Russell Microcap Index on June 27 • The reason for the delisting was actually positive -- Accelerate’s market cap of over $1 billion is too high to be a microcap • This move, however, led to some microcap funds selling shares of Accelerate • Why didn’t the move up to the Russell 2000 small-cap index help? Several funds tracking the index already held shares in Accelerate Why Accelerate Diagnostics’ stock decelerated
  • 5. The stock of this biopharmaceutical firm fell 13% this week. Synageva BioPharma Corp. (NASDAQ:GEVA) Source: Yahoo! Finance
  • 6. • Synageva announced results from a phase 3 study of sebelipase alfa, a drug targeting treatment of patients with lysosomal acid lipase (LAL) deficiency • While the drug met its primary endpoint, concerns arose in particular about one side effect – 17% of patients taking sebelipase alfa experienced Oropharyngeal pain • Some industry observers suspect that even if Synageva wins regulatory approval for the drug, its launch could take a while to achieve success because many patients don’t recognize that they have LAL deficiency Why Synageva’s shares sank
  • 7. Shares of the developer of implantable lenses plunged 15% this week. STAAR Surgical Company (NASDAQ:STAA) Source: Yahoo! Finance
  • 8. • The FDA posted a warning letter to STAAR Surgical dated May 21, 2014 citing 15 design and quality control issues • This warning letter spurred a flurry of “investigations” of STAAR by legal firms • The issues identified by the FDA are primarily procedural ones that seem to be able to be resolved by the company • This week’s sell-off halted a nice 18% run by STAAR that started in mid-May Why STAAR Surgical’s stock plummeted
  • 9. • The pullback in Accelerate Diagnostics’ shares could present a buying opportunity, although Synageva’s prospects seem a bit murkier • STAAR Surgical gets the nod as the stock with the best chance of a strong rebound • This week’s sell-off appears to be overdone and could set up the stock for gains as investors have the opportunity to buy shares at the lowest prices seen so far this year Best shot at bouncing back?
  • 10. Cable’s going away. But do you know how to profit? There’s $2.2 trillion at stake. Find out which 3 companies stand ready to benefit -- and they’re not Netflix, Google, and Apple!